Goldman Sachs
DFTX

Goldman Sachs’s Definium Therapeutics DFTX Stock Holding History

Goldman Sachs’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-39,547
Closed -$1.38M – 6605
2021
Q3 		$1.38M Buy
+39,547
New +$1.71M ﹤0.01% 4500

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs's DFTX Position: Q1 2026 in Review

Goldman Sachs increased its Definium Therapeutics (DFTX) stake by 81% in Q1 2026, buying an estimated $12.7M and bringing the position to 1,675,411 shares worth $31.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2002.

Goldman Sachs first reported a position in DFTX in Q2 2021 and has held it in 20 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Goldman Sachs held 1,675,411 shares of Definium Therapeutics worth $31.7M as of Q1 2026.
  • Goldman Sachs bought 750,079 Definium Therapeutics shares in Q1 2026, an estimated $12.7M.
  • Definium Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2002 holding.
  • Goldman Sachs first reported a position in Definium Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.